ArticlePharmaceuticals (Basel, Switzerland)2026

Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway.

Qingmeng Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.